TRT

MangoRx Officially Launches ‘PRIME’ by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Treatment

Retrieved on: 
Tuesday, March 12, 2024
Growth, Patient, Ageing, TRT, Social media, Telehealth, Athlete, Male, Injection, Erectile dysfunction, Marketing, FDA, National library, Pharmaceutical industry

Dallas, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated hair growth product (‘GROW’) and erectile dysfunction (ED) drug (‘Mango’), is excited to announce the highly anticipated release and availability of ‘PRIME’ by MangoRx, Powered by Kyzatrex®️ (“PRIME”) bringing the FDA-approved oral testosterone replacement therapy (TRT) treatment to consumers across the U.S via its proprietary telehealth platform.

Key Points: 
  • Those interested in speaking with a medical provider to obtain a prescription for PRIME can do so by visiting MangoRx’s website at https://www.mangorx.com/app/prime .
  • Furthermore, the introduction of oral testosterone therapy presents a compelling opportunity to tap into a significant addressable market.
  • By offering an alternative to injectable TRT, oral therapy addresses the concerns of individuals who are hesitant or unwilling to undergo injections.
  • This segment of the market, encompassing those with needle aversion, represents a substantial portion of the population and presents a compelling case for the viability and potential growth of oral testosterone therapy.

Teradek Launches Prism Mobile 5G & Mk II for In The Field Broadcasting

Retrieved on: 
Wednesday, March 27, 2024
Prism, GM, PIX, LTE, Size, CBRS, SIM, TRT, Magic, System, Gold, AVID, Sony, HEVC, Mobile phone

IRVINE, Calif., March 27, 2024 /PRNewswire/ -- Teradek introduces Prism Mobile 5G and Prism Mobile Mk II, the latest additions to its acclaimed Prism Series of 4K HEVC video encoders.

Key Points: 
  • IRVINE, Calif., March 27, 2024 /PRNewswire/ -- Teradek introduces Prism Mobile 5G and Prism Mobile Mk II, the latest additions to its acclaimed Prism Series of 4K HEVC video encoders.
  • The Prism Mobile 5G and Mk II feature 2x integrated high-performance cellular modems (LTE for the Mk II) with private mobile network / CBRS support, twin SIM slots, and an external connection for modem expansion (+1 Node modem).
  • Prism Mobile also brings the Teradek Reliable Transport (TRT) protocol to bonded cellular workflows for the first time.
  • Prism Mobile 5G and Mk II are available for pre-order today.

Teradek Launches Prism Flex Mk II: the Do-It-All Throw Down Encoder for Broadcast and Live Production

Retrieved on: 
Wednesday, March 20, 2024
Cloud, Flex, Prism, RTSP, Communication, RTMP, Decoding, MPEG-TS, SRT, TRT, HLS, RIST, System, Sony, OLED, DASH, Mark II

IRVINE, Calif., March 20, 2024 /PRNewswire/ -- Teradek introduces Prism Flex Mk II, the newest addition to its acclaimed Prism Series.

Key Points: 
  • IRVINE, Calif., March 20, 2024 /PRNewswire/ -- Teradek introduces Prism Flex Mk II, the newest addition to its acclaimed Prism Series.
  • With the Prism Flex Mk II, broadcasters can now:
    Enable intercom with Teradek's Core Cloud platform and other Prism devices.
  • The Prism Flex Mk II continues to offer the same robust live streaming capabilities as the rest of the Prism line, from live video contribution and remote production to post-production workflows.
  • "The Prism Flex Mk II is a bi-product of Teradek's commitment to continuous improvement," said Derek Nickell, Product Manager at Teradek.

MangoRx Launches Direct-To-Clinics Sales Division to Drive and Fuel Customer Acquisition and Revenue Growth

Retrieved on: 
Tuesday, February 20, 2024
Acquisition, Marketing, FDA, Sale, Erectile dysfunction, Testosterone, Patient, TRT, Prescription, Research, Nursing

Dallas, Texas, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug (‘Mango’), its hair growth product (‘GROW’), and its FDA approved oral testosterone replacement therapy (TRT), ‘PRIME’, by MangoRx, powered by Kyzatrex®️, is excited to announce that it has officially launched its direct-to-clinics sales division offering doctors and medical practitioners the ability to prescribe MangoRx products to their patients directly from their offices, clinics and brick and mortar locations. The Company also reports that it has successfully onboarded its first medical health and wellness clinic based in Dallas, TX last week.

Key Points: 
  • The Company also reports that it has successfully onboarded its first medical health and wellness clinic based in Dallas, TX last week.
  • The Company believes that this direct-to-clinics initiative will assist in fueling a greater amount of recurring revenues while at the same time reducing customer acquisition costs (CACs) associated with traditional digital marketing strategies.
  • The Company will be activating a website where providers and clinics can visit to complete the onboarding process to qualify as a MangoRx preferred provider.
  • We are confident that this new initiative will fuel our revenue growth and have a further impact on making MangoRx a household name.”

MangoRx Accepting Pre Orders for its “PRIME”, by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Product

Retrieved on: 
Monday, February 5, 2024
Partnership, Telehealth, Male, TRT, Erectile dysfunction, Safety, Patient, FDA, Marketing, Pharmacy, Testosterone, Lymphatic system, Liver, Barstool Sports, Schedule, Pharmaceutical industry

Dallas, Texas, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated hair growth product (‘GROW’) and erectile dysfunction (ED) drug (‘Mango’), is excited to announce that it is offering 2 months of free ‘PRIME’ by MangoRx, Powered by Kyzatrex®️ (“PRIME”) (a $498 value) for the first 1,000 male subscribers who express interest in subscribing to the oral testosterone replacement protocol.

Key Points: 
  • Those interested in taking advantage of this exclusive offer simply need to visit the sign-up page at https://www.mangorx.com/prime-sign-up/ and submit basic demographic information.
  • Interested subscribers will also be prompted to preorder a minimally invasive FDA approved at-home blood collection test kit through their nationwide lab partnership with Trybe Labs , which is being offered to MangoRx subscribers at preferred discounted prices.
  • ‘PRIME’, by MangoRx, powered by Kyzatrex®️ delivers testosterone in a softgel capsule that is absorbed primarily via the lymphatic system, avoiding liver toxicity.
  • PRIME will be available to MangoRx customers at a price of $199/month with eligibility to receive an additional 10% discount per month if subscribed to another MangoRx product (e.g.

Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals

Retrieved on: 
Friday, February 2, 2024
Central nervous system, FDA, Food, CNS, TRT, Pharmaceutical industry

TLANDO is the first and only oral testosterone replacement therapy (TRT) option approved by the US Food and Drug Administration (FDA) that does not require dose titration.

Key Points: 
  • TLANDO is the first and only oral testosterone replacement therapy (TRT) option approved by the US Food and Drug Administration (FDA) that does not require dose titration.
  • In January 2024, Lipocine and Gordon Silver Limited entered into an exclusive license agreement under which Verity Pharma will market TLANDO® in the United States and, if approved, in Canada.
  • Under the terms of the license agreement, Lipocine has received the second tranche of the $11 million license fee, $5 million.
  • In addition, per the license agreement, Gordon Silver Limited is to make license fee payments of $2.5 million and $1 million no later than January 1, 2025, and January 1, 2026, respectively.

Xinhua Silk Road: Pien Tze Huang, Beijing Tong Ren Tang agree to boost bilateral cooperation, promote high-quality development of TCM

Retrieved on: 
Friday, February 2, 2024
Multimedia, Partner, Conference, TCM, Pien tze huang, TRT, Belt, Pharmaceutical industry

BEIJING, Feb. 1, 2024 /PRNewswire/ -- Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. (Pien Tze Huang) signed a cooperation agreement with Beijing Tong Ren Tang (TRT) Group during the First Conference of Partners of Tong Ren Tang, which was held in Beijing from January 17 to 19.

Key Points: 
  • BEIJING, Feb. 1, 2024 /PRNewswire/ -- Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. (Pien Tze Huang) signed a cooperation agreement with Beijing Tong Ren Tang (TRT) Group during the First Conference of Partners of Tong Ren Tang, which was held in Beijing from January 17 to 19.
  • In the future, they will jointly explore the overseas markets and promote TCM development in the world.
  • "Both Beijing Tong Ren Tang and Pien Tze Huang Pharmaceutical are pacesetters in TCM," said Lin Zhihui, chairman of Pien Tze Huang Pharmaceutical, at the conference on January 18.
  • As a leading TCM enterprise in China, Pien Tze Huang Pharmaceutical is committed to technological innovation and industrial transformation.

MangoRx’s Brand and Products to be Featured by Barstool Sports in Week of Programming Around the Biggest Sports Event of the Year on February 11

Retrieved on: 
Friday, January 19, 2024
Entrepreneurship, Barstool Sports, Internet, Bowl game, Social media, TRT, Radio, Partnership, Super Bowl, Marquee, Softgel, Lymphatic system, FDA, Erectile dysfunction, Running, Liver, Marketing, Testosterone, Pharmaceutical industry

 Dallas, Texas, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (Nasdaq: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated hair growth product (“GROW”) and erectile dysfunction (“ED”) drug (“Mango”), is excited to announce that it will be a Marquee Sponsor for Barstool Sports’ week-long programming schedule surrounding the Big Game in Las Vegas on Sunday, Feb 11, 2024.

Key Points: 
  • In addition, as a Marquee Sponsor, MangoRx will be prominently featured on the Barstool Podcasts starting the week of January 22nd and running through March 15th with an estimated number of over 7 million views and impressions.
  • Dave Portnoy, one of the most recognizable faces in the American sports media industry, founded Barstool Sports, growing the brand into the multi-million-dollar preeminent digital sports media presence.
  • KYZATREX delivers testosterone in a softgel capsule that is absorbed primarily via the lymphatic system, avoiding liver toxicity.
  • KYZATREX is delivered as a softgel capsule that is absorbed primarily via the lymphatic system, avoiding liver toxicity.

Craft Medical Evolves to Craft Men's Clinic, Reflecting Its Dedication to Men's Health

Retrieved on: 
Monday, January 22, 2024
Stearman, Patient, STE, Men's Health, TRT, Health

TULSA, Okla., Jan. 22, 2024 /PRNewswire/ -- Craft Medical, a leader in men's telehealth services, is excited to announce its rebranding to Craft Men's Clinic, a Craft Health Company.

Key Points: 
  • TULSA, Okla., Jan. 22, 2024 /PRNewswire/ -- Craft Medical, a leader in men's telehealth services, is excited to announce its rebranding to Craft Men's Clinic, a Craft Health Company.
  • This change is not just in name but also a reaffirmation of our dedication to men's health and hormone optimization, focusing on online healthcare solutions.
  • Since its inception, Craft Medical has been at the forefront of providing personalized medical care remotely, specializing in testosterone replacement therapy (TRT).
  • "We've always been passionate about men's health, and renaming ourselves Craft Men's Clinic solidifies our commitment to this cause.

Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada

Retrieved on: 
Thursday, January 18, 2024
Central nervous system, Verity, TRT, Health, Central nervous system disease, Prescription, Food, FDA, Marketing, License, CNS, Pharmaceutical industry

The agreement also provides Verity Pharma with the U.S. and Canadian rights to develop and commercialize LPCN 1111 (TLANDO XR), a next generation, once daily oral product candidate for TRT.

Key Points: 
  • The agreement also provides Verity Pharma with the U.S. and Canadian rights to develop and commercialize LPCN 1111 (TLANDO XR), a next generation, once daily oral product candidate for TRT.
  • Under the agreement, Verity Pharma will be responsible for regulatory and marketing obligations in the U.S. and Canada, and all further development.
  • Lipocine retains all rights to the TLANDO franchise for territories outside the U.S. and Canada, and all rights to non-TRT indications globally.
  • "We are very pleased to enter this license agreement with Verity Pharma.